• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miR-451 通过调控乳腺癌中 YWHAZ 表达水平介导紫杉醇耐药。

Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer.

机构信息

Department of Biotechnology, Bengbu Medical College, Anhui 233030, China.

Clinical Testing and Diagnose Experimental Center, Bengbu Medical College, Anhui 233030, China.

出版信息

Cell Death Dis. 2017 Oct 5;8(10):e3071. doi: 10.1038/cddis.2017.460.

DOI:10.1038/cddis.2017.460
PMID:28981108
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5680582/
Abstract

MicroRNAs (miRNAs) have been identified as major post-transcriptional regulators of the initiation and progression of human cancers, including breast cancer. However, the detail role of miR-451 has not been fully elucidated in breast cancer. In this study, we aimed to investigate the biological role and molecular mechanisms of miR-451 in drug resistance in breast cancer cell lines and in xenograft model. We show that miR-451 is decreased in human breast cancer specimens and in paclitaxel-resistant (PR) cells. Ectopic expression of miR-451 could inhibit the cell migration and invasion, promoted apoptosis, induced cell-cycle arrest Furthermore, tyrosine3-monooxygenase/tryptophan5-monooxygenase activation protein zeta (YWHAZ) was identified as a direct target of miR-451. Remarkably, the expression of YWHAZ is inversely correlated with the level of miR-451 in human breast cancer samples. Co-treatment with miR-451 mimics and YWHAZ-siRNA significantly enhanced YWHAZ knockdown in both SKBR3/PR and MCF-7/PR cells Moreover, miR-451 markedly inhibited expression of β-catenin via YWHAZ and subsequently inhibited downstream gene cyclin D1, c-Myc expression. The results of xenograft model in vivo showed that intratumor injection of miR-451 agomir induced a tumor-suppressive effect in SKBR3/PR drug-resistant xenograft model. Taken together, our findings suggested that miR-451 might be considered as important and potential target in paclitaxel-resistant breast cancer treatment.

摘要

微小 RNA(miRNAs)已被确定为人类癌症(包括乳腺癌)发生和发展的主要转录后调控因子。然而,miR-451 在乳腺癌中的详细作用尚未完全阐明。在本研究中,我们旨在研究 miR-451 在乳腺癌细胞系和异种移植模型中的耐药性中的生物学作用和分子机制。我们表明,miR-451 在人乳腺癌标本和紫杉醇耐药(PR)细胞中减少。miR-451 的异位表达可以抑制细胞迁移和侵袭,促进细胞凋亡,诱导细胞周期停滞。此外,酪氨酸 3-单加氧酶/色氨酸 5-单加氧酶激活蛋白 ζ(YWHAZ)被鉴定为 miR-451 的直接靶标。值得注意的是,YWHAZ 的表达与人乳腺癌样本中 miR-451 的水平呈负相关。miR-451 模拟物和 YWHAZ-siRNA 的共同处理显著增强了 SKBR3/PR 和 MCF-7/PR 细胞中 YWHAZ 敲低。此外,miR-451 通过 YWHAZ 显著抑制β-连环蛋白的表达,随后抑制下游基因 cyclin D1、c-Myc 的表达。体内异种移植模型的结果表明,miR-451 激动剂在 SKBR3/PR 耐药异种移植模型中的肿瘤内注射诱导了肿瘤抑制作用。总之,我们的研究结果表明,miR-451 可能被认为是紫杉醇耐药乳腺癌治疗的重要潜在靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/d7ecbdb012f8/cddis2017460f11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/bd7c14452db9/cddis2017460f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/9e0b0d72e81a/cddis2017460f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/039b14642183/cddis2017460f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/b679c3aecd3f/cddis2017460f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/e403ddb1dd83/cddis2017460f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/6c30778faba0/cddis2017460f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/417ebdc5f6cc/cddis2017460f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/f527d9a0db9d/cddis2017460f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/5b81c56a8317/cddis2017460f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/0eddd982d10b/cddis2017460f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/d7ecbdb012f8/cddis2017460f11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/bd7c14452db9/cddis2017460f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/9e0b0d72e81a/cddis2017460f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/039b14642183/cddis2017460f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/b679c3aecd3f/cddis2017460f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/e403ddb1dd83/cddis2017460f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/6c30778faba0/cddis2017460f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/417ebdc5f6cc/cddis2017460f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/f527d9a0db9d/cddis2017460f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/5b81c56a8317/cddis2017460f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/0eddd982d10b/cddis2017460f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abfe/5680582/d7ecbdb012f8/cddis2017460f11.jpg

相似文献

1
Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer.miR-451 通过调控乳腺癌中 YWHAZ 表达水平介导紫杉醇耐药。
Cell Death Dis. 2017 Oct 5;8(10):e3071. doi: 10.1038/cddis.2017.460.
2
Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells.长链非编码 RNA H19 作为 miR-340-3p 的海绵体,通过调节紫杉醇耐药乳腺癌细胞中 YWHAZ 的表达促进上皮-间充质转化。
Environ Toxicol. 2020 Sep;35(9):1015-1028. doi: 10.1002/tox.22938. Epub 2020 May 18.
3
N-peptide of vMIP-Ⅱ reverses paclitaxel-resistance by regulating miRNA-335 in breast cancer.VMIP-Ⅱ 的 N 肽通过调节乳腺癌中的 miRNA-335 逆转紫杉醇耐药性。
Int J Oncol. 2017 Sep;51(3):918-930. doi: 10.3892/ijo.2017.4076. Epub 2017 Jul 19.
4
NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer.NT21MP 通过靶向 CXCR4 通路中的 miR-155-3p 和 miR-155-5p 负调控乳腺癌紫杉醇耐药细胞。
Int J Oncol. 2018 Sep;53(3):1043-1054. doi: 10.3892/ijo.2018.4477. Epub 2018 Jul 9.
5
miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.微小RNA-205靶向血管内皮生长因子A(VEGFA)和成纤维细胞生长因子2(FGF2)并调节乳腺癌对化疗药物的耐药性。
Cell Death Dis. 2016 Jun 30;7(6):e2291. doi: 10.1038/cddis.2016.194.
6
MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.微小RNA 100通过靶向雷帕霉素靶蛋白(mTOR),部分地使腔面A型乳腺癌细胞对紫杉醇治疗敏感。
Oncotarget. 2016 Feb 2;7(5):5702-14. doi: 10.18632/oncotarget.6790.
7
MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).miR-181a 通过靶向乳腺癌耐药蛋白(BCRP/ABCG2)增强米托蒽醌耐药乳腺癌细胞对药物的敏感性。
Breast Cancer Res Treat. 2013 Jun;139(3):717-30. doi: 10.1007/s10549-013-2607-x. Epub 2013 Jun 19.
8
MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer.miR-155-5p 通过 TP53INP1 促进人乳腺癌肿瘤进展并导致紫杉醇耐药。
Pathol Res Pract. 2021 Apr;220:153405. doi: 10.1016/j.prp.2021.153405. Epub 2021 Mar 5.
9
LGR5 acts as a target of miR-340-5p in the suppression of cell progression and drug resistance in breast cancer via Wnt/β-catenin pathway.LGR5 在乳腺癌中作为 miR-340-5p 的靶标,通过 Wnt/β-catenin 通路抑制细胞进展和耐药性。
Gene. 2019 Jan 30;683:47-53. doi: 10.1016/j.gene.2018.10.014. Epub 2018 Oct 6.
10
miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.微小RNA-218靶向存活素并调节乳腺癌对化疗药物的耐药性。
Breast Cancer Res Treat. 2015 Jun;151(2):269-80. doi: 10.1007/s10549-015-3372-9. Epub 2015 Apr 22.

引用本文的文献

1
Extracellular vesicles derived from salivary gland stem cells cultured on microwell scaffolds loaded with WNT3A promote the recovery of salivary gland function damaged by radiation via the YWHAZ-PI3K-AKT pathway.在负载有WNT3A的微孔支架上培养的唾液腺干细胞衍生的细胞外囊泡通过YWHAZ-PI3K-AKT途径促进辐射损伤的唾液腺功能的恢复。
Bioact Mater. 2025 Jun 17;52:492-510. doi: 10.1016/j.bioactmat.2025.06.024. eCollection 2025 Oct.
2
Potential biological roles of exosomal non-coding RNAs in breast cancer.外泌体非编码RNA在乳腺癌中的潜在生物学作用
FASEB J. 2025 Mar 31;39(6):e70456. doi: 10.1096/fj.202500022R.
3
Integrative analysis of aging-related genes reveals CEBPA as a novel therapeutic target in non-small cell lung cancer.

本文引用的文献

1
Metastatic Breast Cancer with BRCA Mutation Discovered By Next-Generation Sequencing Responding to Olaparib.通过下一代测序发现的携带BRCA突变的转移性乳腺癌对奥拉帕尼有反应。
Cureus. 2017 Jun 11;9(6):e1337. doi: 10.7759/cureus.1337.
2
miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer.miR-218-5p通过PRKCE/MDR1轴恢复胆囊癌对吉西他滨的敏感性。
Cell Death Dis. 2017 May 11;8(5):e2770. doi: 10.1038/cddis.2017.178.
3
MicroRNA-200a Suppresses Cell Invasion and Migration by Directly Targeting GAB1 in Hepatocellular Carcinoma.
衰老相关基因的综合分析揭示CEBPA是非小细胞肺癌中的一个新治疗靶点。
Cancer Cell Int. 2024 Jul 27;24(1):267. doi: 10.1186/s12935-024-03457-4.
4
Exploring the role of microRNAs as diagnostic and prognostic biomarkers in canine mammary tumors.探讨 microRNAs 作为犬乳腺肿瘤诊断和预后生物标志物的作用。
Geroscience. 2024 Dec;46(6):6641-6657. doi: 10.1007/s11357-024-01260-7. Epub 2024 Jul 2.
5
TMEM65 promotes gastric tumorigenesis by targeting YWHAZ to activate PI3K-Akt-mTOR pathway and is a therapeutic target.TMEM65 通过靶向 YWHAZ 激活 PI3K-Akt-mTOR 通路促进胃癌发生,是一个治疗靶点。
Oncogene. 2024 Mar;43(13):931-943. doi: 10.1038/s41388-024-02959-9. Epub 2024 Feb 10.
6
Resistance of breast cancer cells to paclitaxel is associated with low expressions of miRNA-186 and miRNA-7.乳腺癌细胞对紫杉醇的耐药性与miRNA - 186和miRNA - 7的低表达有关。
Cancer Drug Resist. 2023 Sep 1;6(3):596-610. doi: 10.20517/cdr.2023.19. eCollection 2023.
7
Regulation of the stem‑like properties of estrogen receptor‑positive breast cancer cells through NR2E3/NR2C2 signaling.通过NR2E3/NR2C2信号传导对雌激素受体阳性乳腺癌细胞干性的调控
Exp Ther Med. 2023 Aug 22;26(4):474. doi: 10.3892/etm.2023.12173. eCollection 2023 Oct.
8
Biological Implications of MicroRNAs as Regulators and Biomarkers of Therapeutic Toxicities in Breast Cancer.miRNAs 在乳腺癌治疗毒性的调控和生物标志物中的生物学意义
Int J Mol Sci. 2023 Aug 11;24(16):12694. doi: 10.3390/ijms241612694.
9
Circ_0069094 regulates malignant phenotype and paclitaxel resistance in breast cancer cells via targeting the miR-136-5p/YWHAZ axis.环状 RNA 0069094 通过靶向 miR-136-5p/YWHAZ 轴调节乳腺癌细胞的恶性表型和紫杉醇耐药性。
Thorac Cancer. 2023 Jul;14(19):1831-1842. doi: 10.1111/1759-7714.14928. Epub 2023 May 16.
10
Landscape of NcRNAs involved in drug resistance of breast cancer.参与乳腺癌耐药的非编码 RNA 景观。
Clin Transl Oncol. 2023 Jul;25(7):1869-1892. doi: 10.1007/s12094-023-03189-3. Epub 2023 Apr 17.
微小RNA-200a通过直接靶向肝细胞癌中的GAB1抑制细胞侵袭和迁移。
Oncol Res. 2017 Jan 2;25(1):1-10. doi: 10.3727/096504016X14685034103798.
4
miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer.miR-96 通过靶向作用于乳腺癌中的 PTPN9 促进细胞增殖、迁移和侵袭。
Sci Rep. 2016 Nov 18;6:37421. doi: 10.1038/srep37421.
5
Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression.微小RNA-27b-3p的下调通过增加NR5A2和CREB1的表达增强乳腺癌对他莫昔芬的耐药性。
Cell Death Dis. 2016 Nov 3;7(11):e2454. doi: 10.1038/cddis.2016.361.
6
miRNA-451 inhibits glioma cell proliferation and invasion by downregulating glucose transporter 1.微小RNA-451通过下调葡萄糖转运蛋白1抑制胶质瘤细胞的增殖和侵袭。
Tumour Biol. 2016 Oct;37(10):13751-13761. doi: 10.1007/s13277-016-5219-3. Epub 2016 Jul 31.
7
MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes.微小RNA-182通过靶向多个基因驱动原发性肉瘤转移。
J Clin Invest. 2016 Apr 1;126(4):1606. doi: 10.1172/JCI86573.
8
Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy.肿瘤抑制基因及其在癌症治疗中对紫杉醇耐药性的潜在相互作用。
Cancer Cell Int. 2016 Feb 20;16:13. doi: 10.1186/s12935-016-0290-9. eCollection 2016.
9
miRNA Deregulation in Cancer Cells and the Tumor Microenvironment.癌细胞和肿瘤微环境中的微小RNA失调
Cancer Discov. 2016 Mar;6(3):235-46. doi: 10.1158/2159-8290.CD-15-0893. Epub 2016 Feb 10.
10
RETRACTED: MicroRNA-138 modulates metastasis and EMT in breast cancer cells by targeting vimentin.撤回:微小RNA-138通过靶向波形蛋白调节乳腺癌细胞的转移和上皮-间质转化。
Biomed Pharmacother. 2016 Feb;77:135-41. doi: 10.1016/j.biopha.2015.12.018. Epub 2015 Dec 29.